Search results
H. Michael Shepard (born 1949) is an American cancer researcher who was awarded the 2007 Harvard Medical School Warren Alpert Foundation Prize and the 2019 Lasker Clinical research award, which he shared with Dennis Slamon and Axel Ullrich for their development of Herceptin
Mar 15, 2024 · In this World View, H. Michael Shepard describes his personal story behind the discovery of trastuzumab, 25 years since its FDA approval for HER2-overexpressing breast cancers.
Dr. Michael Shepard is an orthopaedic surgeon who specializes in the treatment of knee, elbow and shoulder injuries in Orange and Irvine.
The 2019 Lasker~DeBakey Clinical Medical Research Award honors three scientists—H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich —who invented Herceptin, the first monoclonal antibody that blocks a cancer-causing protein, and developed it into a life-saving therapy for women with breast cancer.
Sep 10, 2019 · H. Michael Shepard, Dennis Slamon, and Axel Ullrich are being recognized for their work toward the development of Herceptin, the first targeted-mAb therapy for cancer. Photo of Axel Ullrich courtesy of the Mary and Albert Lasker Foundation. Go to: The hunt for cancer-causing genes and therapeutic strategies.
Shepard was also scientific program leader for Halozyme’s Phase 3 candidate for pancreatic cancer (Pegylated PH20 hyaluronidase). Shepard currently consults with several biopharmaceutical companies, primarily on cancer therapeutics discovery and early clinical development.
Oct 8, 2019 · In September, UC Davis alum Michael Shepard and his colleagues received the 2019 Lasker-DeBakey Clinical Medical Research Award for the groundbreaking foundational research that led to the creation of Herceptin.
